CHINO HILLS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC:SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that it has acquired:
ABBIE, a world-class gene-editing platform which can deliver genetic payloads using non-viral vectors.
With this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023. The gene-editing market is expected to grow to $10.8 billion by 2028 at a 15% CAGR. (Source: 2023, Marketsandmarkets.com.)
ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell's genome. ABBIE will be able to edit genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and cell engineering technologies.
ABBIE is currently undergoing further development to optimize expression and purification of its protein-based platform. Upon completion of development, ABBIE will become high-quality, off-the-shelf cell engineering kits. Gene-editing companies will use ABBIE kits to deliver a gene payload to a specific locus on their targeted cells.
Revenue generations can be obtained immediately through licensing and gene-editing kits slated to be released for commercialization in 3Q/4Q 2024. ABBIE is expected to reach in-human trial on or before 4Q 2025.
The global biotechnology kit market is estimated at $593 billion in 2022 and projected to grow at a 10.9% CAGR between 2023 and 2030. (Source: 2023, GrandViewResearch.com.)
ABBIE's development is being led by David Aguilar ...